Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial

Arthritis and Rheumatism

Volumn 64, Issue 2, 2012, Pages 360-370

  Tak, P P ^a   Mease, P J ^b   Genovese, M C ^c   Kremer, J ^d   Haraoui, B ^e   Tanaka, Y ^f   Bingham, C O ^g   Ashrafzadeh, A ^h   Travers, H ⁱ   Safa Leathers, S ⁱ   Kumar, S ⁱ   Dummer, W ^h  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Seattle Rhumatology Associates   (United States)

^c STANFORD UNIVERSITY   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

^e NOTRE DAME HOSPITAL   (Canada)

^f UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h GENENTECH INC   (United States)

ⁱ ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; FOLIC ACID; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; OCRELIZUMAB; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; BACTERIAL ARTHRITIS; BLOOD DISEASE; CELLULITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEPATITIS B; HUMAN; INFECTION; INJURY; LUNG TUBERCULOSIS; LYMPHATIC SYSTEM DISEASE; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEOPLASM; OPPORTUNISTIC INFECTION; PHASE 3 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863012323     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33353     Document Type: Article

References (24)

1. Silverman GJ, Weisman S,. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003; 48: 1484-92. (Pubitemid 36682354)
2. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81. (Pubitemid 38758544)
3. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-400.
4. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806. (Pubitemid 44497758)
5. Clark EA, Shu G, Ledbetter JA,. Role of the Bp35 cell surface polypeptide in human B-cell activation. Proc Natl Acad Sci U S A 1985; 82: 1766-70. (Pubitemid 15085258)
6. Ocrelizumab [data on file]. South San Francisco (CA): Genentech; 2003.
7. Genovese MC, Kaine JL, Lowenstein MB, Del Giudice J, Baldassare A, Schechtman J, et al, for the ACTION Study Group. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58: 2652-61.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. (Pubitemid 18091653)
9. Rigby W, Tony HP, Oelke K, Combe B, Laster A, von Muehlen C, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 2012; 64: 350-9.
10. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
11. Van der Heijde DM, van Riel PL, Gribnau FW, Nuver-Zwart IH, van de Putte LB,. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; 1: 1036-8. (Pubitemid 19123055)
12. Fries JF, Spitz P, Kraines RG, Holman HR,. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45. (Pubitemid 10164318)
13. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
14. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders [SERENE]) [published erratum appears in Ann Rheum Dis 2011;70:1519]. Ann Rheum Dis 2010; 69: 1629-35.
15. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition [published erratum appears in N Engl J Med 2005;353:2311]. N Engl J Med 2005; 353: 1114-23. (Pubitemid 41317434)
16. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67: 1516-23.
17. Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011; 70: 39-46.
18. Landewe R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S,. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006; 54: 3119-25. (Pubitemid 44622081)
19. Keystone EC, Emery P, Peterfy CG, Tak PP, Cohen SB, Genovese MC, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies [published erratum appears in Ann Rheum Dis 2011;70:1519]. Ann Rheum Dis 2009; 68: 216-21.
20. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP,. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008; 67: 917-25. (Pubitemid 351956651)
21. Dorner T, Kinnman N, Tak PP,. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther 2010; 125: 464-75.
22. Vugmeyster Y, Beyer J, Howell K, Combs D, Fielder P, Yang J, et al. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J Immunother 2005; 28: 212-9. (Pubitemid 40593986)
23. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174: 817-26. (Pubitemid 40094277)
24. Emery P, Rigby W, Tak PP, Dorner T, Genovese MC, Ferraccioli G, et al. Serious infections with ocrelizumab in rheumatoid arthritis: pooled results from double-blind periods of the ocrelizumab phase III RA program [abstract]. Arthritis Rheum 2010; 62 Suppl: S175.